
Vaxcyte (PCVX) Stock Forecast & Price Target
Vaxcyte (PCVX) Analyst Ratings
Bulls say
Vaxcyte Inc. has demonstrated a positive outlook supported by an updated peak revenue estimate of $6.8 billion by 2040, reflecting confidence in market adoption for its vaccine candidates. The anticipated launch of VAX-31 in 2028, along with strong Phase 1/2 results, positions the company favorably to capture a significant addressable market, particularly among adults over 50 years old with potential ACIP recommendations. Additionally, positive clinical data from both adult and infant studies of VAX-31 is expected to enhance investor interest and support a favorable stock performance in the near term.
Bears say
Vaxcyte Inc is confronted with significant downside risks, including potential delays in research and development, regulatory hurdles, and lower-than-expected clinical results that could hinder its product pipeline advancements. Recent clinical trial outcomes, particularly the VAX-24 Phase 2 readout, have underwhelmed investors, contributing to a negative perception of the company's prospects in the competitive pediatric vaccine market. Additionally, national vaccine guidelines may not endorse Vaxcyte's products even if they succeed in clinical trials, thereby limiting their commercial viability and potential market uptake.
This aggregate rating is based on analysts' research of Vaxcyte and is not a guaranteed prediction by Public.com or investment advice.
Vaxcyte (PCVX) Analyst Forecast & Price Prediction
Start investing in Vaxcyte (PCVX)
Order type
Buy in
Order amount
Est. shares
0 shares